Abstract
a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
Introduction
In the last few decades, individualized treatment has played a significant role in the management of breast cancer patients. Such interventions, focused on targeting specific biological features of tumors, constitute a very effective strategy for the resolution of malignancies. The human epithelial growth factor receptor 2 (HER2) oncoprotein, along with the hormone receptors (HR) estrogen receptor (ER) and progesterone receptor (PR), are mediators of two key pathways involved in breast carcinogenesis, invasive behavior and cell growth, and have previously been validated as therapeutic targets [1, 2] .
Breast cancer is a molecularly heterogenous disease and several different sub-types have been defined based on cell receptor expression profiles. Approximately 25% of all female breast cancers exhibit an over-expression of HER2, which is known to drive aggressive cellular behavior [3] [4] [5] [6] [7] . Trastuzumab (a monoclonal antibody), the first-line of treatment for HER2+ breast cancers [8] [9] [10] , has been shown to be active as a single agent [11, 12] as well as in combination with chemotherapy [9, 10, 13] for the treatment of advanced stage HER2+ breast cancer. Its use has been shown to positively affect patient outcomes such as progression-free survival (PFS) and overall survival (OS). HR signaling pathways play an equally important role in breast cancer oncogenesis and advancement [1, 2] . HR+ breast cancers account for about 70% of all invasive female breast malignancies and generally respond well to endocrine therapy [1, 7] . However, side effects such as resistance to either HER2-targeted therapy or hormonal therapy along with other issues such as an increased cardiotoxicity caused by trastuzumab represent pressing clinical issues that pertain to the use of these drugs and the mechanisms for primary or acquired resistance to such therapies are probably multifactorial [1, [14] [15] [16] [17] .
Previous literature has demonstrated that the targeted treatment of HER2+ breast tumors is associated with an increased resistance to endocrine treatment [18] . Since triple positive HR +/HER2+ breast cancer patients tend to be less responsive to endocrine therapy [19] , we propose that extensive interactions exist between the HER2 signaling pathway and the ER signaling pathways and a large body of recent literature supports this hypothesis [19] [20] [21] [22] [23] . Studies report that once growth stimuli (including ligands), bind to the HER2 receptor, a series of intracellular signaling pathways are activated. These mainly include the PI3K/Akt/mTOR and MAPK/ERK signal pathways, downregulating ER expression via phosphorylation of the PI3K/ Akt/mTOR signal pathway and phosphorylating ER Ser118 via activation of the MAPK/ERK pathway, which correlates with the poor clinical outcomes of breast cancers [2, 22, 24, 25] . Our study might enable the identification of the possible mechanism by which HER2 expression participates in the resistance to endocrine treatment.
In addition, the ER co-activator Mediator Subunit 1 (MED1) has been found to be a novel critical cross-talk point for the HER2 and ER signaling pathways within the cell and is amplified or overexpressed in more than 50% of all primary breast cancers [26, 27] . It has been demonstrated that the MED1 gene, localized on chromosome 17q12, is required for ER-dependent endogenous reporter gene expression and estrogen-dependent breast cancer cell growth [28] [29] [30] [31] [32] . Certain studies have reported that MED1 amplification or overexpression is significantly associated with poor outcomes in breast cancer patients treated with hormone therapy [33] . It also plays a critical role in the development of tamoxifen resistance, which is in turn linked with HER2 amplification or overexpression [30] . Experiments (both in vitro and in vivo) have demonstrated that a knockdown of MED1 sensitizes breast cancer cells to fulvestrant treatment [27] . Much literature has confirmed that the ER co-activator MED1 often co-amplifies with HER2 in primary breast cancers [26, 27] and that HER2 amplification or overexpression can enhance MED1 phosphorylation by activating the MAPK/ERK pathway, thus affecting ER activity [34] [35] [36] .
Data from clinical studies has shown that the majority of HR+/HER2+ breast cancer patients are minimally responsive to endocrine therapy and it is also well known that HER2 positivity plays a critical role in the resistance to hormonal therapy [18, 19] . In addition, the cardiotoxic effects of trastuzumab such as decreased left ventricular ejection fraction, congestive heart failure and even death are commonly encountered in routine clinical practice [37, 38] . As reported by C. Kent Osborne in the American Society of Clinical Oncology (ASCO) Annual Meeting on June 4 2016, studies on crosstalk between estrogen and growth factor receptor pathways may reveal new strategies to overcome endocrine therapy resistance. Therefore, targeting the ER and HER2 receptors simultaneously is likely to be a fruitful approach for the treatment of HR+/HER2+ (triple positive) breast cancer, and the occurrence of side effects may decrease significantly in this combination application. As fulvestrant, a selective ER down-regulator, remains active in HER2+ breast cancer cells that are resistant to other endocrine treatments and is licensed for advanced breast cancer in postmenopausal women after recurrence or progression despite previous endocrine treatments, it is possible that HER2 amplification or overexpression may have a different impact upon the activity of fulvestrant compared with tamoxifen or other hormone-regulating drugs [39] [40] [41] [42] . Therefore, in this work, we test the effects of trastuzumab (herceptin) and fulvestrant (falsodex) as a combination in the HR+/HER2+ breast cancer cell lines ZR-75-1 and BT-474 as well as in mouse tumor xenografts.
Materials and Methods

Drugs and Cells
Trastuzumab (herceptin) and fulvestrant (falsodex) were purchased from Roche (Basel, Switzerland) and AstraZeneca (London, England), respectively, and stored at 4˚C according to manufacturer's instructions. The HR+/HER2+ breast cancer cell lines ZR-75-1 and BT-474 were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and the Cell Resource Center (Beijing, China), respectively. Cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (PS) in a 37˚C, 5% CO 2 fully humidified incubator. In addition, 0.01mg/ml of insulin was added in order to culture BT-474 cells.
Ethical Considerations
Nude mice were used as animal models in order to study the effects of trastuzumab combined with fulvestrant in HR+/HER2+ breast cancer. All experiments were carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals (National Institutes of Health). The protocol was approved by the Committee for the Ethics of Animal Experiments of the Xinhua Hospital, affiliated to Shanghai Jiao Tong University School of Medicine, China. Surgeries were performed using sodium pentobarbital as an anesthetic and animals were sacrificed by CO 2 asphyxiation. Every effort was made in order to minimize animal suffering. 
Cell Proliferation Inhibition Rate
Analysis of Synergy
Data from the CPIR assay was analyzed using the CalcuSyn software. Combination index (CI) and dose-reduction index (DRI) at a 50% inhibition effect level were calculated from the effects of varying doses on cell proliferation inhibition rates. CI is a quantitative measure of the degree of drug interaction and may be classified in terms of additive effect (CI = 1), synergism (CI < 1), or antagonism (CI > 1) for a given endpoint [43] . DRI is a measure of how much the dose of each drug in a synergistic combination may be reduced at a given effect level compared with doses of each drug when used as single agents.
Analysis of Apoptotic Rate by Flow Cytometry
ZR-75-1 and BT-474 cells (in the exponential growth phase) were seeded in 6-well plates. After the cells adhered to the bottom of the plates, they were either left untreated, treated with a vehicular control, trastuzumab at 0.65mg/ml in ZR-75-1 cells and 0.13mg/ml in BT-474 cells, or fulvestrant at 45nmol/L in ZR-75-1 cells and 34nmol/L in BT-474 cells, or a combination of trastuzumab at 0.65mg/ml and fulvestrant at 45nmol/L in ZR-75-1 cells or trastuzumab at 0.13mg/ml and fulvestrant at 34nmol/L in BT-474 cells. After 72h, cells were collected and stained with annexin V-fluorescein isothiocyanate (Annexin V-FITC) and propidium iodide (PI) using the annexin V-FITC/PI apoptosis detection kit (BD Pharmingen; San Diego, CA, USA) in accordance with manufacturer's instructions. Flow cytometric analysis was performed using the BD FACS Calibur Cell Sorting System (BD Pharmingen; San Diego, CA, USA) and results were analyzed using the FlowJo 7.6.1 software.
Analysis of Cell Cycle progression by Flow Cytometry
After treatment with the same concentrations and combinations of both drugs as used in previous experiments, cells were collected, washed and re-suspended in ice-cold PBS and fixed using 70% ethanol at 4˚C for over 24h. Thereafter, cells were centrifuged, re-suspended in ice cold PBS and then stained with PI using the cell cycle and apoptosis analysis kit (Beyotime Biotechnology, China) at 37˚C for 30 minutes. Cells were then detected using the BD FACSCalibur CellSorting System and results were analyzed using FlowJo 7.6.1 software.
Analysis of Protein Expression by Immunoblotting
Three days after treatment, cell proteins in all groups were extracted separately. Protein samples (50μg) were separated on a 10% SDS-PAGE gel and then transferred to a PVDF membrane. Subsequently, membranes were blocked using BSA. This was followed by incubation in primary antibodies at 1:1000 dilution in TBS-Tween (TBST) (0.05% Tween-20 in TBS) at 4˚C overnight on a shaker. Anti-phospho-Akt (Ser-473) (#4060), anti-phospho-p44/42 MAPK (Erk1/2) (Thr 202/Try 204) (#4370), anti-Akt (#9272), anti-p44/42 MAPK (Erk1/2) (#9102) and anti-GAPDH (#2118) antibodies were purchased from Cell Signaling Technology (USA).
Membranes were then incubated in secondary peroxidase-conjugated antibody dilution buffer (Cell Signaling Technology, USA) and processed using immobilon western chemiluminescence HRP substrate kit (Millipore, USA). 
Mouse Xenograft Studies
Immunoblot Analysis of Proteins p-MED1 and MED1 Expressed in Tumor Tissues
Frozen tumor tissues were ground and lysed in RIPA buffer on ice until no en bloc tissues remained. Lysates were micro-centrifuged at 12,000 rpm for 15 min at 4˚C, and supernatants were maintained and stored at -80˚C after measuring protein concentrations. Procedures for immunoblot analysis were the same as described previously. Anti-phospho-TRAP 220/MED1 (T1457) antibody (#ab181103, Abcam, UK), anti-TRAP 220/MED1 antibody (#AF 5520-SP, R&D, USA) and anti-α/β-Tubulin antibody (#2148, Cell Signaling Technology, USA) at a dilution of 1:1000 in TBST were used.
Statistical Analysis
All experiments conducted as part of the in vitro cell culture study were repeated three times and those conducted as part of the in vivo study were repeated twice, of which one representative result has been included within the supplementary section of the manuscript, since similar results were obtained in all repeats. Statistical Package for the Social Sciences (SPSS) 19.0 software (SPSS Inc., Chicago, IL, USA) was used for analysis and data obtained from multiple independent experiments were expressed as mean ± SD. Statistical differences between the size of tumors before and after treatment was computed using t test and other data was computed using Dunnett's test (for data following normal distribution) or Dunnett's test (for data following non-normal distribution). A P-value<0.05 was considered statistically significant.
Results
Cell Proliferation Inhibition Rate
Drug dose versus cell proliferation inhibition rate curves for ZR-75-1 cells and BT-474 cells (either untreated or in the presence of trastuzumab or fulvestrant or both) are shown in Fig 1. As no statistical differences between the effects on the vehicle groups and control groups were observed in both cell lines, data from the vehicle group has not been shown. In both cell lines, trastuzumab and fulvestrant as single agents caused an increase in the rate of cell proliferation inhibition with increasing drug concentrations (P<0.05), and their combination led to a much stronger effect compared with the use of individual drugs(P<0.05).
Analyses of the combined use of trastuzumab and fulvestrant conducted using the CalcuSyn software are shown in Table 1 . 50% effective dose (ED 50 ) of trastuzumab and fulvestrant in individual drug experiments were applied in subsequent experiments. At ED 50 levels, the combination index (CI) was <1 and the dose-reduction index (DRI) was >1 in both cell lines. Table 1 .
Effects on Cell Apoptosis
It was clear that fulvestrant as a single agent or combined with trastuzumab induced both, early stage apoptosis (P<0.001 for both) and late stage apoptosis (P = 0.013 for the fulvestranttreated group and P = 0.002 for combination group) in BT-474 cells. However, no statistical differences in the rates of cell apoptosis were observed between the two groups receiving fulvestrant as a single agent or in combination with trastuzumab (Fig 2 and Table 2 ). Besides, no increase in the rate of cellular apoptosis was observed in the trastuzumab-treated group for the BT-474 cell line (Fig 2 and Table 2 ) and in all the treatment groups for ZR-75-1 cell line (Fig 3 and Table 3 ). 
Effects on Cell Cycle Progression
The distribution of ZR-75-1 cells in different phases of the cell cycle after 72h drug treatments is shown in Fig 4 and Table 4 , and that of BT-474 cells is shown in Fig 5 and Table 5 . In our experiments, the use of trastuzumab and fulvestrant either as single agents or in combination promoted an accumulation of both ZR-75-1 and BT-474 cells in the G 1 phase of the cell cycle (compared with control group (P<0.05)). The combination of trastuzumab and fulvestrant caused a statistically significant further increase in the percentage of ZR-75-1 cells in the G 1 phase compared with the effect of fulvestrant alone (P = 0.030), but no significant differences were observed between the trastuzumab-treated group and the combination group (P>0.05). Analysis of the distribution of the BT-474 cells in different phases of the cell cycle indicated that no statistically significant differences were detected between the combination group and individual drug-treatment groups(P>0.05).
Immunoblot Analysis of Downstream Signaling Pathways
In work with proteins extracted from ZR-75-1 cells (Fig 6) , levels of the p-Akt protein decreased in the trastuzumab-treated group (Tras vs. Con, P = 0.037) and the levels of p-Akt and p-Erk increased in the fulvestrant-treated group (Ful vs. Con, P = 0.005 for p-Akt and P = 0.025 for p-Erk). The combination of trastuzumab and fulvestrant significantly reduced pAkt protein levels (Com vs. Con, P = 0.020) and notably also inhibited the effect of fulvestrant on the increased levels of p-Akt and p-Erk (Com vs. Ful, P = 0.046 for p-Akt and P = 0.025 for p-Erk). For samples extracted form BT-474 cells (Fig 7) , trastuzumab as a single agent or in combination with fulvestrant reduced the levels of p-Akt and p-Erk proteins (Tras vs. Con, P = 0.029 for p-Akt and P = 0.033 for p-Erk; Com vs. Con, P = 0.019 for p-Akt and P = 0.038 for p-Erk). Fulvestrant, however, raised protein expression levels (Ful vs. Con, P = 0.015 for pAkt and P = 0.047 for p-Erk). The combination of trastuzumab and fulvestrant significantly inhibited the effects of fulvestrant on protein expression levels (Com vs. Ful, P = 0.001 for pAkt and p-Erk). is also noteworthy that BT-474 tumor xenografts were so sensitive to the combination treatment that several tumors in the combination treatment group almost disappeared after fourweek treatment (with much lower drug doses than those used for mice bearing ZR-75-1 tumor xenografts), leaving a cavity in place of the xenografts. In addition, weight change curves of nude mice in ZR-75-1 (S5A Fig) and BT-474 (S5B Fig) tumor xenograft models showed that the weight of the mice in both animal models in all groups did not change significantly through the entire treatment process (P>0.05). . p-Akt and p-Erk proteins from two samples in the control group and vehicle group and from three samples in each treatment group were detected. It was found that trastuzumab decreased p-Akt levels and that fulvestrant increased both, p-Akt and p-Erk levels. In addition, the combination of both drugs significantly reduced levels of p-Akt and notably inhibited the effect that fulvestrant had on the levels of both proteins. * P<0.05 compared with control group. ** P<0.05 compared with combination group.
Immunoblot Analysis of Proteins Expressed in Tumor Tissues
Since levels of the protein p-MED1 (the phosphorylated form of the Mediator Complex Subunit 1) detected within the two cell lines were too low to allow the quantification of any variations caused due to drug treatment, we analyzed this parameter in mouse tumor xenograft tissues using immunobloting. As shown in Fig 9, trastuzumab and fulvestrant, either as single agents or in combination decreased the levels of the p-MED1 (phosphorylated MED1) protein expressed in ZR-75-1 tumor xenografts (P<0.001 for all the treatment groups compared with vehicle-treated group), and simultaneously increased expression levels of total MED1 protein (Tras vs. vehicle, P<0.001; Ful vs. vehicle, P = 0.011; Com vs. vehicle, P = 0.010). However, no statistically significant differences in both p-MED1 and MED1 protein expression levels were observed between the combination and individually treated groups (P>0.05). Results from the BT-474 tumor xenograft model shown in Fig 10 indicate that the level of protein p-MED1 in all treatment groups decreased compared with vehicle-treated group (P<0.001), and that the combination group expressed lower levels of p-MED1 than that the fulvestrant-treated group (P = 0.039). Besides, trastuzumab combined with fulvestrant could enhance the expression of total protein MED1 (P = 0.017). Therefore, it is possible that trastuzumab acts in synergy with fulvestrant in HR+/HER2+ breast cancer by suppressing the activation of the protein MED1.
Discussion
Our results highlight the effects of trastuzumab (herceptin) and fulvestrant (falsodex) as single agents or in combination on the cell proliferation rates of HR+/HER2+ human breast cancer cell lines ZR-75-1 and BT-474. We show that these effects are concentration-dependent, and that treatment with a combination of both drugs results in a synergistic inhibition of cell growth in culture. This demonstration of synergy between trastuzumab and fulvestrant on human cancer cell lines has not been reported previously. Besides, the doses of both drugs decrease in the combined application (with DRI>1 at ED 50 ), increasing the likelihood that the occurrence of side effects will reduce when used in combination physiologically. Further experiments that were conducted as part of this work sought to investigate the basis and extent of this synergistic effect and thus experiments on cell apoptosis, cell cycle progression and downstream cell signaling pathways were carried out. An analysis of drug effects on the rate of cell apoptosis using the Annexin-V/PI assay indicated that fulvestrant, either as a single agent or in combination with trastuzumab promotes BT-474 cell apoptosis. However, no significant differences in apoptotic rate between the fulvestrant-treated group and the combination groups were observed. In addition, no effect on the rate of BT-474 cell apoptosis was observed upon the administration of trastuzumab alone. Therefore, in this case, the combination of trastuzumab and fulvestrant did not have a synergistic, pro-apoptotic effect and any increase in the rate of BT-474 apoptosis observed could be attributed to the use of fulvestrant alone. Moreover, neither drug was capable of inducing apoptosis in the ZR-75-1 cell line. Thus, although both cell lines used were HR+/HER2+, they responded differently to therapy in our experiments. This is an important consideration even Previous studies have reported that when trastuzumab and fulvestrant are used as single agents, they promote an accumulation of cells in the G1 phase of the cell cycle [44] and we confirmed these results in our experiments on both cell lines. In addition, an increased effect on the accumulation of cells in the G1 phase was observed in the combination group compared with the fulvestrant-treated group in the ZR-75-1 cell line. However, in our experiments on the BT-474 cell line, no significant differences were observed between combination and individually treated groups.
Several previous studies have documented that trastuzumab inhibits the activation of the downstream signaling pathways involving PI3K/Akt/mTOR and MAPK/Erk [45, 46] , and we report similar results in our work. We observed that trastuzumab treatment decreased levels of the protein p-Akt in both cell lines and also decreased levels of the protein p-Erk in BT-474 cells. Besides, both p-Akt and p-Erk were found to be overexpressed in ZR-75-1 as well as BT-474 cells after fulvestrant treatment but notably decreased from these levels when combined with trastuzumab, implying that the combination of trastuzumab and fulvestrant significantly prevented fulvestrant from increasing the levels of these proteins in HR+/HER2+ breast cancer. Since the activation of PI3K/Akt/mTOR and MAPK/Erk signaling pathways correlates with worse clinical outcomes in breast cancer [47, 48] , our results suggest that HR+/HER2 + breast cancer patients receiving co-targeted therapies including trastuzumab and fulvestrant in combination could probably have a better prognosis than those receiving fulvestrant alone. Consistent with the results from in vitro experiments reported in this work, in vivo studies using ZR-75-1 and BT-474 tumor xenografts showed that both, trastuzumab and fulvestrant as single agents inhibited tumor growth. In addition, their combination resulted in an enhanced inhibition compared to either drug alone and apart from preventing further tumor growth, even effectively shrank pre-existing tumors. Moreover, it is noteworthy that the BT-474 tumor xenografts were extremely sensitive to the combination of trastuzumab and fulvestrant and we show that several tumors in the combination treatment group almost disappeared after a fourweek long treatment with a much lower drug concentration than was used for mice bearing ZR-75-1 tumor xenografts. Hence, the combination of trastuzumab and fulvestrant is synergistic and effectively inhibits HR+/HER2+ breast cancer tumor growth in vivo.
Using ZR-75-1 and BT-474 mouse tumor xenograft models, we showed that trastuzumab and fulvestrant as single agents or in combination could also significantly inhibit the activation of MED1 and that their combination resulted in a much stronger inhibition than fulvestrant alone in work with BT-474 tumor xenograft model. This difference in response to the two drugs can most likely be attributed to the fact that the BT-474 cell line is known to express much higher levels of HER2, which is the molecular target of trastuzumab [49] . However, in our work with the ZR-75-1 tumor xenograft model, no significant differences were observed between the combination group and single agent-treated groups. This was probably due to the fact that the initial doses of trastuzumab and fulvestrant used were already saturating. The lack of difference observed between individual and combined treatment groups could also be attributed to the lengthy duration of treatment. Importantly, the activation of MED1 has been shown to correlate with poor clinical outcomes in breast cancer patients treated with endocrine therapy [33] and our results indicate that trastuzumab and fulvestrant may improve the prognosis of HR+/HER2+ breast cancer patients by inhibiting the activation of MED1.
Fulvestrant, a novel endocrine modulator, has been reported to remain active even after recurrence or progression with previous endocrine treatments in postmenopausal women [40] [41] [42] 45] . Therefore, the combination of trastuzumab and fulvestrant, which had positive synergistic effects in our experiments, may constitute an improved course of treatment for HR +/HER2+ advanced breast cancer resistant to previous hormone therapies. 
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